Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis

Autologous hematopoietic stem cell transplantation (aHSCT) is the only treatment for refractory autoimmune diseases capable of inducing long-term, drug-free and asymptomatic remission. Over the past two decades, aHSCT has been used to treat inflammatory autoimmune disease of the CNS. Patients with relapsing-remitting multiple sclerosis benefit from aHSCT treatment. However, a certain percentage of patients still experience recurrence 3 or 5 years after transplantation. Therefore, exploration of conditioning regimens will drive therapeutic advances in aHSCT in autoimmune diseases of the CNS.

NCT Number	NCT06228781
Lead Sponsor	Tianjin Medical University General Hospital
Conditions	Multiple Sclerosis
Enrollment	20 participants
Start Date	2026-12-01
Primary Completion	2029-01-01 (estimated)
Study Completion	2029-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-30